WallStreetZenWallStreetZen

NASDAQ: GNTA
Genenta Science Spa Stock

Overview
ForecastEarningsRevenueDividendOwnership
$4.04+0.12 (+3.06%)
Updated Apr 25, 2025
GNTA Price
$4.04
Fair Value Price
N/A
Market Cap
$73.89M
52 Week Low
$2.55
52 Week High
$7.28
P/E
-7.58x
P/B
5.44x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$9.28M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.19
Operating Cash Flow
-$7M
Beta
0.38
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

GNTA Overview

Genenta Science S.p.A. is a clinical-stage biotechnology company developing hematopoietic stem cell gene therapies for the treatment of solid tumors. The company's lead product candidate is Temferon, in Phase 1/2a clinical trials for the treatment of glioblastoma multiforme in patients with an unmethylated MGMT gene promoter. Genenta Science was incorporated in 2014 and is headquartered in Milan, Italy.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine GNTA's potential to beat the market

View All “A” Zen Rated Stocks
→

Zen Rating Component Grades

N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
GNTA
RankedUnranked of 460

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
Protalix Biotherapeutics (PLX)
$2.85A
Aurinia Pharmaceuticals (AUPH)
$8.18A
Catalyst Pharmaceuticals (CPRX)
$23.45A
View Top Biotech Stocks

Be the first to know about important GNTA news, forecast changes, insider trades & much more!

GNTA News

Overview

Due Diligence Score

–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GNTA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

GNTA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GNTA is poor value based on its book value relative to its share price (5.44x), compared to the US Biotechnology industry average (4.26x)
P/B vs Industry Valuation
GNTA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more GNTA due diligence checks available for Premium users.

Valuation

GNTA fair value

Fair Value of GNTA stock based on Discounted Cash Flow (DCF)

Price
$4.04
Fair Value
$0.22
Overvalued by
1,745.58%
GNTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

GNTA price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-7.58x
Industry
-157.91x
Market
29.65x

GNTA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
5.44x
Industry
4.26x
GNTA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

GNTA's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
GNTA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$15.4M
Liabilities
$2.4M
Debt to equity
0.19
GNTA's short-term assets ($15.73M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GNTA's short-term assets ($15.73M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GNTA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GNTA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
GNTA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

GNTA vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
GNTA–$73.89M+3.06%-7.58x5.44x
ANL–$73.54M+5.00%2.15x1.38x
CRVOF$75.19M-1.82%-4.28x1.92x
STROD$75.65M-30.54%-0.31x1.70x
CRBUD$71.99M-11.34%-0.47x0.28x
View Top Biotech Stocks

Genenta Science Spa Stock FAQ

What is Genenta Science Spa's quote symbol?

(NASDAQ: GNTA) Genenta Science Spa trades on the NASDAQ under the ticker symbol GNTA. Genenta Science Spa stock quotes can also be displayed as NASDAQ: GNTA.

If you're new to stock investing, here's how to buy Genenta Science Spa stock.

What is the 52 week high and low for Genenta Science Spa (NASDAQ: GNTA)?

(NASDAQ: GNTA) Genenta Science Spa's 52-week high was $7.28, and its 52-week low was $2.55. It is currently -44.51% from its 52-week high and 58.43% from its 52-week low.

How much is Genenta Science Spa stock worth today?

(NASDAQ: GNTA) Genenta Science Spa currently has 18,289,866 outstanding shares. With Genenta Science Spa stock trading at $4.04 per share, the total value of Genenta Science Spa stock (market capitalization) is $73.89M.

Genenta Science Spa stock was originally listed at a price of $11.00 in Dec 15, 2021. If you had invested in Genenta Science Spa stock at $11.00, your return over the last 3 years would have been -63.27%, for an annualized return of -28.39% (not including any dividends or dividend reinvestments).

How much is Genenta Science Spa's stock price per share?

(NASDAQ: GNTA) Genenta Science Spa stock price per share is $4.04 today (as of Apr 25, 2025).

What is Genenta Science Spa's Market Cap?

(NASDAQ: GNTA) Genenta Science Spa's market cap is $73.89M, as of Apr 26, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Genenta Science Spa's market cap is calculated by multiplying GNTA's current stock price of $4.04 by GNTA's total outstanding shares of 18,289,866.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.